SandemanStocks
Concentrated Growth-Stock Investor
Moderna stands to benefit from weeks of media fear over hantavirus because it has an early-stage vaccine. With an incubation period of about eight weeks, the coverage should persist even though the threat looks overblown, making this a very risky, high-upside bet to exit before sentiment turns. In a clip shared by @FurkanGozukara, Dr. Pierre Kory notes over 100,000 hantavirus articles were published globally in days. x.com
Moderna looks like a logical play on plague-outbreak concerns, though this is outside areas of expertise. A Russian lab worker's sudden death has raised fears of a plague crisis, per Zero Hedge, with the Trump team monitoring the outbreak, and the stock is acting well. x.com
Moderna could fly on hantavirus fears, with a potential case in Illinois from rodent exposure, unrelated to the cruise ship. The stock has a long base, and the longer the base the bigger the move, plus huge short interest. x.com
Moderna's data catalyst is done, and it won't get an early stop in RCC. That makes it a good short here, with the story over until at least next summer. x.com
Moderna could get explosive above $200 as anyone who shorted last week's valuation downgrade has to cover. The shakeout on that downgrade was a killer opportunity, and the stock is now back over $200. x.com
Moderna could rise further with strong call flow showing, but it is getting close to a top expected in late October or early November; take profits on the way up. x.com
Moderna is a stock to bet against. x.com
Moderna is extremely attractive because curing cancer is a big story, but more consolidation is likely first. The weekly chart shows a wide gap between price and the upper Bollinger Band, so volatility may need another week or two to ebb before the stock possibly starts moving higher. x.com
Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.com
Moderna looks overvalued at about $80B after its melanoma success sparked a retail frenzy. Its upcoming Phase 2 lung cancer and Phase 3 kidney cancer readouts target cold tumors, with much lower odds than melanoma, though success in either would fuel the rally further. January calls cost about 67% of the share price annualized, the most expensive option seen on an already overvalued stock. The retail-driven trend could continue in the short term. x.com
Moderna's next push is cancer vaccines after its COVID-19 run. The stock is about to enter a re-accumulation stage, a chance to buy heavily before another huge move, and a single article could send it higher. x.com
